Nuvalent, Inc.

NUVL

US6707031075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
104.80 ^USD	-1.05%		-4.38%	+33.88%

12-10	Nuvalent Insider Sold Shares Worth $781,537, According to a Recent SEC Filing	MT
12-10	Nuvalent, Inc. Announces Board Changes	CI

Nuvalent announces public offering of common stock

Published on 11/17/2025 at 09:13 pm GMT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Nuvalent, Inc.

12-10	Nuvalent Insider Sold Shares Worth $781,537, According to a Recent SEC Filing	MT
12-10	Nuvalent, Inc. Announces Board Changes	CI
12-02	Nuvalent Insider Sold Shares Worth $434,319, According to a Recent SEC Filing	MT
11-25	Nuvalent Insider Sold Shares Worth $70,874,975, According to a Recent SEC Filing	MT
11-24	Nuvalent Closes Public Offering of Common Shares	MT
11-19	Nuvalent Insider Sold Shares Worth $2,552,999, According to a Recent SEC Filing	MT
11-19	Nuvalent Insider Sold Shares Worth $2,065,030, According to a Recent SEC Filing	MT
11-19	Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer	MT
11-19	Nuvalent Files New Drug Application for Lung Cancer Treatment With FDA	DJ
11-19	Nuvalent announces FDA acceptance of new drug application for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC	RE
11-19	Nuvalent, Inc. Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced Ros1-Positive NSCLC	CI
11-19	Nuvalent Prices $500 Million Common Stock Offering	MT
11-19	Nuvalent prices 4.95 million shares in public offering at $101.00 per share	RE
11-18	Wedbush Raises Price Target on Nuvalent to $125 From $120, Keeps Outperform Rating	MT
11-17	Nuvalent Launches Public Offering of Shares	MT
11-17	Nuvalent announces public offering of common stock	RE
11-17	Barclays Raises Nuvalent Price Target to $152 From $112, Equalweight Rating Kept	MT
11-17	Nuvalent Says Neladalkib Offers Clinical Benefit in Phase 1/2 ALK-Positive Lung Cancer Trial	MT
11-17	Nuvalent reports positive ALKOVE-1 trial data for neladalkib in ALK-positive NSCLC patients	RE
11-17	Nuvalent, Inc. - Special Call
11-17	Nuvalent, Inc. Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK- Positive NSCLC	CI
11-14	Nuvalent announces timing of topline pivotal data for TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 clinical trial of Neladalkib	RE
11-12	Canaccord Genuity Initiates Coverage on Nuvalent With Buy Rating, $126 Price Target	MT
10-31	UBS Adjusts Price Target on Nuvalent to $132 From $114, Maintains Buy Rating	MT
10-30	Nuvalent, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

Employees

218

Sector

Biotechnology & Medical Research

Calendar

03-03 - Q4 2025 Earnings Release (Projected)

More about the company